ALLO - Allogene Therapeutics, Inc.

1.55
-0.020   -1.290%

Share volume: 1,086,380
Last Updated: 04-25-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$1.57
-0.02
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
36%
Profitability 35%
Dept financing 5%
Liquidity 58%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.73%
1 Month
0   0%
3 Months
-19.69%
6 Months
-42.16%
1 Year
-45.42%
2 Year
-71.45%
Key data
Stock price
$1.55
P/E Ratio 
0.00
DAY RANGE
$1.52 - $1.59
EPS 
-$1.32
52 WEEK RANGE
$1.23 - $3.78
52 WEEK CHANGE
-$45.42
MARKET CAP 
446.602 M
YIELD 
N/A
SHARES OUTSTANDING 
209.112 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
2.13
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,871,274
AVERAGE 30 VOLUME 
$2,677,098
Company detail
CEO: David D. Chang
Region: US
Website: allogene.com
Employees: 310
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Recent news
loading